Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin-binding protein C, fast-type (MYBPC2) is an accessory component of the thick filament in vertebrate striated muscle, specifically enriched in fast skeletal muscle. It is part of the myosin-binding protein C family, which comprises fast-, slow-, and cardiac-type isoforms, each encoded by separate genes. MYBPC2 localizes to the cross-bridge-bearing C region of the A-band and is fundamental for proper sarcomeric architecture, modulating the speed, force, and calcium sensitivity of muscle contraction. The protein engages in specific protein-protein interactions through conserved modular domains, binding both myosin (particularly subfragment 2) and actin, and thereby subtends both structural and regulatory roles within the sarcomere. Genetic mutations in MYBPC2 can result in skeletal myopathies such as distal arthrogryposis, and its absence leads to defective contractile function and compromised muscle regeneration and integrity[2][4][5][6]. Unlike its cardiac and slow skeletal counterparts, MYBPC2 (fast skeletal MyBP-C) is not currently targeted by drugs and is not a known direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin-binding protein C, fast-type (MYBPC2).